Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (5589)	10/24/1998 4:01:00 PM
From: Steve Fancy	Respond to of 6136

Izzy, you're hitting on AGPH's known weakness....communication. Check out the divisional stock proposal page. It's been under construction and in check back mode for at least the last 30 days. You would think this would be a high priority IR item at this point. I didn't check the pipeline pages, but assuming you didn't miss anything, seems inexcusable to not list everything in the works and some kind of status. Investors love to see a company lay out cash with no progress reporting. All that said, I'm pretty darn happy with the stock at the moment. sf

To: Izzy who wrote (5589)	10/24/1998 6:20:00 PM
From: sim1	Respond to of 6136

You have to wander around a bit. From the AGPH home page click on Investor Relations, then on Information Fact Sheet. From the AGPH Fact Sheet... <<<<<<<<<< Non-nucleoside Reverse Transcriptase Inhibitor Developing new compounds that improve upon the efficacy, safety and resistance profiles of currently availableagents is an importantt goal in the evolving treatment of HIV infection. Agouron will develop and commercialize a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection. Discovered by shionogi & Co., Lte., Osaka, Japan, this compound (AG1549) is currently the subject of several clinical trials evaluating its dose and its concomitant use with other antiretroviral treatments. Agouron will move swiftly to initiate additional clinical trials to further evaluate its utility in the treatment of HIV. >>>>>>>>>> <<<<<<<<<< PRODUCT PIPELINE NAME ENZYME TARGET AG1661 HIV-1 Immunogen Clin: PIII AG3340 Matrix metalloprotease (MMP) inhibitor for cancer Clin: PIII AG1549 Non-nucleoside reverse transcriptase inhibitor Clin: PII AG3340 Matrix metalloprotease inhibitor for ophthalmic disease (acute macular degeneration) Clin: PII AG2037 GART inhibitor backup Preclinical AG7088 Rhinovirus 3C protease inhibitor for respiratory Preclinical infections (common cold) AG1776 HIV protease inhibitor Preclinical MMP third generation Preclinical PARP enzyme inhibitors for cancer Research cdk4/cdk2 inhibitors for cancer Research Hepatitis C protease inhibitors Research VEGF receptor for cancer and ophthalmic disease Research GnRH antagonist for cancer Research HIV integrase inhibitors Research >>>>>>>> (Sorry for the table formatting) They also have a Research page with brief summaries of work in that area. From their Research page, <<<<<<<<<<<< HIV Integrase for HIV Infection Development Status: Research HIV integrase is one of three viral-encoded enzymes required for replication of HIV inside a host cell (the two other enzymes are reverse transcriptase and protease). The life cycle of HIV begins when HIV attaches itself to the membrane of the target host cell, enters the cytoplasm of the cell, and then reverse-transcribes itself into viral copy DNA (cDNA) using reverse transcriptase. Integrase then integrates, or inserts, the viral cDNA into the chromosomal DNA of the infected host cell. Only when integration is complete is the proviral HIV DNA then able to direct the production of new viral proteins and the assembly of these viral proteins into new viral particles. Integration is therefore a critical step in the completion of the viral life cycle and subsequent production of new viral particles. Agouron scientists believe that blocking HIV integrase is a viable therapeutic strategy that will abort completion of the viral life cycle, preventing infection of new, uninfected target cells. Scientists also believe that HIV integrase is an attractive target, because it is extremely unlikely an HIV integrase-specific inhibitor will nonspecifically inhibit other eukaryotic enzymes. This fact may possibly reduce the incidence of side effects of an integrase inhibitor used to treat HIV infection. >>>>>>>>>>>>

To: Izzy who wrote (5589)	10/25/1998 12:40:00 AM
From: tnsaf	Read Replies (1) \| Respond to of 6136

The August 10-K has much of what you want. Although I didn't see Thymitaq mentioned by name, the new name for S-1153 is given as AG1549. Here is the URL for the "Business" section of the 10-K: freeedgar.com Jason

To: Izzy who wrote (5589)	10/27/1998 3:02:00 AM
From: John Romeo	Read Replies (1) \| Respond to of 6136

My understanding is per company press releases this will be a 2nd generation protease inhibitor your dates are right. I'm sure when the time comes they will mix and match this with many other drugs including viracept.We'll just have to wait. Last summer at the Geneva conference i believe,this was the one where Sustiva killed the P.I. company's, agph came out with a number of new co-partnered new drug candidates.Development in this order,Remune,NNRTI,2nd generation P.I. japan. The company made it clear after the conference they will not rest with just viracept, their intent is to build an HIV franchise.Somewhat like Glaxo is doing Now. I agree with you this product numbering, naming is confusing I'll email or call and ask to update the site if more people do it, it can be done, we need more than 2 emails or phone calls, so everyone rise to the occasion. regards John L. R.